Brain Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and agree to follow the study requirements by signing a consent form.
• People who have been confirmed by tissue or pathology testing to have non-small cell lung cancer (a type of lung cancer) that has stopped responding to treatment, including both a specific genetic type (EGFR wild-type) and another genetic type (EGFR mutant).
• People who have 5 or fewer spots of cancer that have spread to the brain, with at least one of those spots visible and measurable on a scan, and whose overall health allows them to receive a precise form of targeted radiation treatment called stereotactic radiosurgery.
• People aged between 18 and 80 years old (any gender).
• People who are relatively well and able to carry out daily activities, as measured by a standard medical scale (ECOG score of 0 or 1), and who are expected to live for at least 3 months.
• People who are able to take a medication called anlotinib by mouth at the same time as receiving radiation therapy (regardless of what other treatments they have had before or after).
• People receiving anlotinib as a third-line treatment or later (meaning other treatments have been tried first).
• People whose major organs are functioning well enough to meet specific blood test requirements, including: healthy red blood cell, white blood cell, and platelet levels; liver enzyme, bilirubin, and kidney function levels within acceptable ranges; and normal blood clotting test results (confirm specific values with the trial site).

Who may not be able to join:

• People with a type of lung cancer called squamous cell carcinoma (or adenosquamous carcinoma) who also have either a hollow cavity in the lung tumour, or who have coughed up a significant amount of blood in the past month, or who have other signs of serious bleeding or a known tendency to bleed.
• People whose cancer has spread widely across the lining of the lungs, into the sac around the heart, or extensively along the spinal cord.
• People who have had another type of cancer in the past 5 years, except for certain fully cured skin or localised cancers (confirm with trial site).
• People who currently have lung inflammation (pneumonia) rated as moderate or worse on a standard medical scale.
• People who have difficulty swallowing, have had part of their digestive system surgically removed, have ongoing severe diarrhoea, or have a blocked bowel, as these conditions may affect the ability to take oral medication.
• People who have signs of active bleeding or an unexplained ongoing drop in red blood cell levels.
• People who have had a significant bleeding event (rated Grade 3 or higher on a standard medical scale) in the 4 weeks before starting the study, or who are currently taking blood-thinning medications such as warfarin or heparin (low-dose preventive use may be allowed — confirm with trial site).
• People who have unhealed wounds, broken bones, active stomach or bowel ulcers, bowel inflammation, bleeding from a tumour that has not been removed, or who have had major surgery in the 4 weeks before starting the study.
• People who have taken certain Chinese herbal or anti-tumour medicines, or immune-modulating drugs, within 2 weeks before starting the study (specific medicines are listed — confirm with trial site).
• People who have previously had an organ or blood cell (bone marrow) transplant.
• People who currently have active inflammation of pouches in the bowel wall (diverticulitis), an abdominal abscess, or a blocked bowel.
• People with serious or uncontrolled health conditions, including: high blood pressure that is not well controlled; a blood clot, stroke, or heart attack in the past 6 months; moderate or severe heart failure; heart rhythm problems requiring treatment; active or severe infections; active hepatitis B or C infection with detectable virus levels; HIV infection; syphilis (confirmed by a specific blood test); poorly controlled diabetes; or significant amounts of protein in the urine.
• People who, in the opinion of the lead doctor running the trial, have other serious circumstances — such as a serious mental health condition, major abnormal test results, or personal or family situations — that could affect their safety or the reliability of study data.

Important: Always verify eligibility with the trial site directly before applying.